AJOVista’s Terns Pharmaceuticals TERN Stock Holding History

AJOVista’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-8,943	Closed	-$58K	–	385
2023 Q4	$58K	Buy	+8,943	New	+$47.3K	0.07%	269

Other funds holding TERN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

AJOVista's TERN Position: Q1 2024 in Review

AJOVista sold out of Terns Pharmaceuticals (TERN) in Q1 2024, closing a stake of 8,943 shares — an estimated $58K sold.

AJOVista first reported a position in TERN in Q4 2023 and held it in 1 quarter. The position peaked at $58K in Q4 2023. 112 funds tracked by Wall St. Rank hold TERN as of Q1 2024.

AJOVista reported no remaining Terns Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
AJOVista sold 8,943 Terns Pharmaceuticals shares in Q1 2024, an estimated $58K.
AJOVista first reported a position in Terns Pharmaceuticals in Q4 2023 and held it in 1 quarter.
AJOVista's Terns Pharmaceuticals position peaked at $58K in Q4 2023.
112 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2024.

Based on AJOVista's 13F filing for Q1 2024, filed 10 May 2024.